<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5082-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIGAVEL 300 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        53.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TABUK PHARMACEUTICAL MANUFACTURING CO." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TABUK PHARMACEUTICAL MANUFACTURING CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CIGALAH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Cigavel belongs to a group of medicines known as angiotensin-II receptor<br />antagonists. Angiotensin-II is a substance produced in the body which binds to<br />receptors in blood vessels causing them to tighten. This results in an increase<br />in blood pressure. Cigavel prevents the binding of angiotensin-II to these<br />receptors, causing the blood vessels to relax and the blood pressure to lower.<br />Cigavel slows the decrease of kidney function in patients with high blood<br />pressure and type 2 diabetes.<br />Cigavel is used:<br />- To treat high blood pressure (essential hypertension).<br />- To protect the kidney in hypertensive type 2 diabetic patients with<br />laboratory evidence of impaired renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Do not take Cigavel<br />- If you are allergic (hypersensitive) to irbesartan or any other ingredients of<br />Cigavel.<br />- If you are more than 3 months pregnant. (It is also better to avoid Cigavel<br />in early pregnancy).<br />Cigavel should not be given to children and adolescents (under 18 years).<br />Take special care with Cigavel<br />Tell your doctor if any of the following apply to you:<br />- If you suffer from excessive vomiting or diarrhea.<br />- If you suffer from kidney problems.<br />- If you suffer from heart problems.<br />- If you receive Cigavel for diabetic kidney disease. In this case your doctor<br />may perform regular blood tests, especially for measuring blood potassium<br />levels in case of poor kidney function.<br />- If you are going to have an operation (surgery) or be given anesthetics.<br />- You must tell your doctor if you think that you are (or might become)<br />pregnant. Cigavel is not recommended in early pregnancy and must not be<br />taken if you are more than 3 months pregnant, as it may cause serious harm<br />to your baby if used at that stage.<br />Taking other medicines<br />Please tell your doctor or pharmacist if you are taking or have recently taken<br />any other medicines, including medicines obtained without a prescription.<br />Cigavel does not usually interact with other medicines.<br />You may need to have blood checks if you take:<br />- Potassium supplements.<br />- Salt substitutes containing potassium.<br />- Potassium-sparing medicines (such as certain diuretics).<br />- Medicines containing lithium.<br />If you take certain painkillers, called non-steroidal anti-inflammatory drugs,<br />the effect of Cigavel may be reduced.<br />Taking Cigavel with food and drink<br />Cigavel can be taken with or without food. The tablets should be swallowed<br />with a drink of water.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant.<br />Your doctor will normally advise you to stop taking Cigavel before you<br />become pregnant or as soon as you know you are pregnant and will advise you<br />to take another medicine instead of Cigavel. Cigavel is not recommended in<br />early pregnancy, and must not be taken when more than 3 months pregnant, as<br />it may cause serious harm to your baby if used after the third month of<br />pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding.<br />Cigavel is not recommended for mothers who are breast-feeding, and your<br />doctor may choose another treatment for you if you wish to breast-feed,<br />especially if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />No studies on the effects on the ability to drive and use machines have been<br />performed. Cigavel is unlikely to affect your ability to drive or use machines.<br />However, occasionally dizziness or weariness may occur during treatment of<br />high blood pressure. If you experience these, talk to your doctor before<br />attempting such activities.<br />Important information about some of the ingredients of Cigavel<br />Cigavel contains lactose. If you have been told by your doctor that you<br />have an intolerance to some sugars, contact your doctor before taking<br />this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Always take Cigavel exactly as your doctor has told you. You should check<br />with your doctor or pharmacist if you are not sure.<br />Method of administration<br />Cigavel is for oral use and is taken with or without food. The tablets should be<br />swallowed with a drink of water. You should try to take your daily dose at<br />about the same time each day. It is important that you continue to take Cigavel<br />until your doctor tells you otherwise.<br />Patients with high blood pressure<br />The usual dose is 150 mg once a day. The dose may later be increased to 300<br />mg once daily depending on blood pressure response.<br />Patients with high blood pressure and type 2 diabetes with kidney disease<br />In patients with high blood pressure and type 2 diabetes, 300 mg once daily is<br />the preferred maintenance dose for the treatment of associated kidney disease.<br />The doctor may advise a lower dose, especially when starting treatment in<br />certain patients such as those on hemodialysis, or those over the age of 75<br />years.<br />The maximal blood pressure lowering effect should be reached 4-6 weeks after<br />beginning treatment.<br />Children should not take Cigavel<br />Cigavel should not be given to children (&lt;18 years).<br />If you take more Cigavel than you should<br />If you accidentally take too many tablets, or a child swallows some, contact<br />your doctor immediately. Symptoms of overdose can be hypotension and<br />tachycardia; bradycardia.<br />If you forget to take Cigavel<br />If you accidentally miss a daily dose, just take the next dose as normal. Do not<br />take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Like all medicines, Cigavel can cause side effects, although not everybody<br />gets them.<br />Some of these effects may be serious and may require medical attention.<br />As with similar medicines, rare cases of allergic skin reactions (rash,<br />urticaria), as well as localized swelling of the face, lips and/or tongue have<br />been reported in patients taking irbesartan. If you get any of these symptoms<br />or get short of breath, stop taking Cigavel and contact your doctor<br />immediately.<br />The frequency of the side effects listed below is defined using the following<br />convention:<br />Very common: Affects more than 1 user in 10.<br />Common: Affects 1 to 10 users in 100.<br />Uncommon: Affects 1 to 10 users in 1,000.<br />Rare: Affects 1 to 10 users in 10,000.<br />Very rare: Affects less than 1 user in 10,000.<br />Not known: frequency cannot be estimated from the available data.<br />Side effects reported in clinical studies for patients treated with irbesartan<br />were:<br />Very common: If you suffer from high blood pressure and type 2 diabetes<br />with kidney disease, blood tests may show an increased level of potassium.<br />Common: Dizziness, feeling sick/vomiting, fatigue and blood tests may show<br />raised levels of an enzyme that measures the muscle and heart function<br />(creatine kinase enzyme). In patients with high blood pressure and type 2<br />diabetes with kidney disease, dizziness when getting up from a lying or sitting<br />position, low blood pressure when getting up from a lying or sitting position,<br />pain in joints or muscles and decreased levels of a protein in the red blood<br />cells (hemoglobin) were also reported.<br />Uncommon: Heart rate increased, flushing, cough, diarrhea,<br />indigestion/heartburn, sexual dysfunction (problems with sexual performance),<br />chest pain.<br />Some side effects have been reported since marketing of irbesartan but the<br />frequency for them to occur is not known. These side-effects are: Headache,<br />taste disturbance, ringing in the ears, muscle cramps, pain in joints and<br />muscles, abnormal liver function, increased blood potassium levels, impaired<br />kidney function, and inflammation of small blood vessels mainly affecting the<br />skin (a condition known as leukocytoclastic vasculitis).<br />If any of the side effects gets serious, or if you notice any side effects not<br />listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Store below 30&deg;C.<br />Do not use beyond the expiry date or if the product shows any sign of<br />deterioration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Cigavel 150 mg: Each film coated tablet contains: Irbesartan 150 mg.<br />Cigavel 300 mg: Each film coated tablet contains: Irbesartan 300 mg.<br />Excipients: Lactose, croscarmellose sodium, microcrystalline cellulose,<br />colloidal silicon dioxide, magnesium stearate, HPMC, PEG, titanium dioxide<br />and simethicone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Packs of 30 Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Manufactured by: Tabuk Pharmaceutical Manufacturing CO.,<br />Madina Road, P.O. Box 3633, Tabuk-Saudi Arabia.<br />For: Cigalah Pharma, Jeddah-Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي سقاڤيل إلى مجموعة من الأدوية تعرف بمضادات مستقبل أنجيوتنسن<br />هو مادة يتم إنتاجها في الجسم التي ترتبط بمستقبلاتها في الأوعية الدموية II أنجيوتنسن<br />مؤدية إلى انقباضها، وهذا يؤدي إلى ارتفاع ضغط الدم. يعمل سقاڤيل على منع ارتباط<br />بهذه المستقبلات، مما يؤدي إلى إرخاء الأوعية الدموية و انخفاض ضغط II أنجيوتنسن<br />الدم. يعمل سقاڤيل على إبطاء انخفاض وظيفة الكلى عند المرضى الذين يعانون من ارتفاع<br />ضغط الدم و النوع الثاني من داء السكري.<br />يستعمل سقاڤيل في الحالات التالية:<br />- لعلاج ارتفاع ضغط الدم )ارتفاع ضغط الدم الأساسي(.<br />- لحماية الكلى عند المرضى الذين يعانون من ارتفاع ضغط الدم و النوع الثاني من داء<br />السكري مع وجود دليل مخبري على قصور وظيفة الكلى لديهم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال سقاڤيل<br />- إذا كنت تعاني من الحساسية )فرط الحساسية( لإربيسارتان أو لأي مكونات أخرى في<br />سقاڤيل.<br />- إذا كنت حامل لمدة تزيد عن 3 شهور. )يفضل أيضاً تجنب تناول سقاڤيل خلال الأشهر<br />الثلاثة الأولى من الحمل(.<br />يجب عدم إعطاء سقاڤيل للأطفال والمراهقين )الأقل من 18 سنة(.<br />الاحتياطات عند تناول سقاڤيل<br />أخبر الطبيب إذا كان أي من التالي ينطبق عليك:<br />- إذا كنت تعاني من قيء أو إسهال شديد.<br />- إذا كنت تعاني من مشاكل في الكلى.<br />- إذا كنت تعاني من مشاكل في القلب.<br />- إذا كنت تتناول سقاڤيل لعلاج مرض الكلى الناتج عن داء السكري. في هذه الحالة قد يقوم<br />الطبيب بعمل فحوصات للدم بانتظام، خصوصاً لقياس مستويات البوتاسيوم في الدم في<br />حالة قصور وظيفة الكلى.<br />- إذا كنت ستخضع لعملية جراحية أو سيتم إعطاؤك مخدر.<br />- يجب عليك إخبار الطبيب إذا كنت تعتقدين بأنك حامل )أو من المحتمل حصول الحمل(. لا<br />يوصى باستعمال سقاڤيل خلال الأشهر الثلاثة الأولى من الحمل ويجب عدم تناوله إذا كنت<br />حامل لمدة تزيد عن 3 شهور، حيث قد يؤدي استعماله في هذه الفترة إلى حدوث ضرر<br />خطير على الجنين.<br />تناول أدوية أخرى<br />الرجاء إخبار طبيبك أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما فيها<br />الأدوية التي يتم الحصول عليها دون وصفة طبية.<br />لايتفاعل سقاڤيل عادة مع الأدوية الأخرى.<br />قد تحتاج للقيام بفحوصات دم إذا كنت تتناول أي مما يلي:<br />- مكملات البوتاسيوم.<br />- بدائل الملح التي تحتوي على البوتاسيوم.<br />- الأدوية الحافظة للبوتاسيوم )مثل مدرات بول معينة(.<br />- أدوية تحتوي على الليثيوم.<br />قد ينخفض مفعول سقاڤيل إذا كنت تتناول مسكنات ألم معينة تعرف بالأدوية غير الستيرويدية<br />المضادة للالتهاب.<br />تناول سقاڤيل مع الطعام و الشراب<br />من الممكن تناول سقاڤيل مع أو دون تناول الطعام. يجب القيام ببلع الأقراص مع شرب الماء.<br />الحمل و الإرضاع<br />استشيري طبيبك أو الصيدلاني قبل تناول أي دواء.<br />الحمل<br />يجب عليك إخبار الطبيب إذا كنت تعتقدين بأنك حامل )أو من المحتمل حصول الحمل(.<br />سينصحك الطبيب عادة بالتوقف عن تناول سقاڤيل قبل حصول الحمل أو في حال حصوله و<br />سينصحك بتناول دواء آخر بدلاً من سقاڤيل. لا يوصى باستعمال سقاڤيل خلال الأشهر<br />الثلاثة الأولى من الحمل ويجب عدم تناوله إذا كنت حامل لمدة تزيد عن 3 شهور، حيث قد<br />يؤدي استعماله بعد الشهر الثالث من الحمل إلى حدوث ضرر خطير على الجنين.<br />الإرضاع<br />أخبري طبيبك إذا كنت مرضعة أو على وشك البدء بالإرضاع. لا يوصى باستعمال سقاڤيل<br />للأمهات المرضعات، وقد يختار لك الطبيب علاج آخر إذا كنت ترغبين في الإرضاع،<br />خصوصاً إذا كان طفلك حديث الولادة أو ولد قبل أوانه.<br />قيادة المركبات و استخدام الآلات<br />لا يوجد دراسات حول التأثير على القدرة على القيادة و استخدام الآلات. من غير المحتمل<br />أن يؤثر سقاڤيل على قدرتك على القيادة أو استخدام الآلات. ولكن، قد يحدث أحياناً شعور<br />بالدوار أو الإرها خلال فترة علاج ارتفاع ضغط الدم. إذا حصل لديك أي من ذلك، يجب<br />عليك إخبار طبيبك قبل محاولة القيام بمثل هذه الأنشطة.<br />معلومات مهمة حول بعض مكونات سقاڤيل<br />يحتوي سقاڤيل على اللاكتوز. إذا أخبرك الطبيب بأنك لا تستطيع تحمل بعض أنواع السكريات،<br />قم بالاتصال بالطبيب قبل البدء بتناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائماً تناول سقاڤيل تمام اً كما أخبرك الطبيب. يجب عليك التأكد من طبيبك أو الصيدلاني إذا<br />لم تكن متأكداً.<br />طريقة الاستعمال<br />يتم تناول سقاڤيل عن طريق الفم مع أو دون تناول الطعام. يجب القيام ببلع الأقراص مع<br />شرب الماء. يجب محاولة تناول الجرعة اليومية في نفس الوقت من كل يوم تقريباً. من<br />الضروري الاستمرار في تناول سقاڤيل حتى يخبرك الطبيب بغير ذلك.<br />المرضى الذين يعانون من ارتفاع ضغط الدم<br />تبلغ الجرعة المعتادة 150 ملجم مرة واحدة يومياً. قد يتم زيادة الجرعة لاحقاً لتصل إلى<br />300 ملجم مرة واحدة يومياً بالاعتماد على استجابة ضغط الدم.<br />المرضى الذين يعانون من ارتفاع ضغط الدم و النوع الثاني من داء السكري مع مرض في<br />الكلى<br />المرضى الذين يعانون من ارتفاع ضغط الدم و النوع الثاني من داء السكري، 300 ملجم<br />مرة واحدة يومياً هي الجرعة المحافظة الأفضل لعلاج مرض الكلى المصاحب لحدوثهما.<br />قد ينصح الطبيب بتناول جرعة أقل، خصوصاً عند البدء بعلاج مرضى معينين كأولئك الذين<br />يخضعون للديلزة الدموية، أو أولئك الذين تزيد أعمارهم عن 75 سنة.<br />6 أسابيع من بدء العلاج. - يجب الوصول إلى الحد الأقصى للتأثير الخافض لضغط الدم بعد 4<br />يجب عدم تناول سقاڤيل من قبل الأطفال<br />يجب عدم إعطاء سقاڤيل للأطفال )&gt; 18 سنة(.<br />إذا تناولت سقاڤيل أكثر مما يجب<br />إذا قمت بتناول عدد كبير من الأقراص عن طريق الخطأ، أو قام طفل ببلع بعضها، قم<br />بالاتصال بطبيبك على الفور. من أعراض فرط الجرعة انخفاض ضغط الدم، تسرع القلب،<br />بطء القلب.<br />إذا نسيت تناول جرعة سقاڤيل<br />إذا نسيت تناول جرعتك اليومية عن طريق الخطأ، فقط تناول الجرعة التالية كالمعتاد. لا<br />تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، قد يسبب سقاڤيل آثاراً جانبية، على الرغم من عدم حدوثها لدى الجميع.<br />قد تكون بعض هذه الآثار خطيرة وقد تحتاج إلى عناية طبية.<br />كما هو الحال مع الأدوية المشابهة، تم تسجيل حدوث حالات نادرة من التفاعلات الجلدية<br />التحسسية )طفح، شرى(، وكذلك تورم موضعي في الوجه، الشفاه و/أو اللسان عند المرضى<br />الذين يتناولون إربيسارتان. إذا حصل لديك أي من هذه الأعراض أو حصل لديك قصر في<br />النفس، توقف عن تناول سقاڤيل و اتصل بطبيبك على الفور.<br />تم تحديد تكرار حدوث الآثار الجانبية المذكورة في الأسفل تبع اً للتصنيف التالي:<br />شائعة جداً: تؤثر على أكثر من شخص من كل 10 أشخاص.<br />شائعة: تؤثر على 1 إلى 10 أشخاص من كل 100 شخص.<br />غير شائعة: تؤثر على 1 إلى 10 أشخاص من كل 1000 شخص.<br />نادرة: تؤثر على 1 إلى 10 أشخاص من كل 10000 شخص.<br />نادرة جداً: تؤثر على أقل من شخص من كل 10000 شخص.<br />غير معروفة: لا يمكن تقدير تكرار حدوثها من المعلومات المتوفرة.<br />تم تسجيل الآثار الجانبية التالية في الدراسات السريرية على المرضى الذين عولجوا<br />بإربيسارتان:<br />شائعة جداً: إذا كنت تعاني من ارتفاع ضغط الدم و النوع الثاني من داء السكري مع مرض<br />في الكلى، قد ت ظهر فحوصات الدم ارتفاع مستوى البوتاسيوم.<br />شائعة: الشعور بالدوار، الغثيان/القيء، الشعور بالتعب و قد ت ظهر فحوصات الدم ارتفاع<br />مستويات الإنزيم الذي يشير إلى صحة عمل القلب و العضلات )إنزيم كرياتين كاينيز(. عند<br />المرضى الذين يعانون من ارتفاع ضغط الدم و النوع الثاني من داء السكري مع مرض في<br />م<br />م<br />الكلى، تم تسجيل أيضاً الشعور بالدوار عند القيام من وضع الاستلقاء أو وضع الجلوس،<br />انخفاض ضغط الدم عند القيام من وضع الاستلقاء أو وضع الجلوس، ألم في المفاصل أو<br />العضلات و انخفاض مستويات البروتين في خلايا الدم الحمراء )الهيموغلوبين(.<br />غير شائعة: ازدياد سرعة القلب، احمرار الوجه، سعال، إسهال، عسر الهضم/حرقة في<br />المعدة، عجز جنسي )مشاكل في الأداء الجنسي(، ألم في الصدر.<br />تم تسجيل بعض الآثار الجانبية خلال فترة تسويق إربيسارتان لكن تكرار حدوثها غير<br />معروف. هذه الآثار الجانبية هي: الصداع، اضطراب حاسة التذو ، رنين في الأذنين،<br />معص عضلي، ألم في المفاصل و العضلات، خلل في وظيفة الكبد، ارتفاع مستويات<br />بوتاسيوم الدم، قصور وظيفة الكلى، و التهاب الأوعية الدموية الصغيرة الذي يؤثر بشكل<br />رئيسي على الجلد )حالة تعرف بفرط حساسية الأوعية الدموية(.<br />إذا ازدادت حدة أي من الآثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه<br />النشرة، الرجاء أن تخبر طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ في درجة حرارة أقل من 30 &deg;م.<br />لا تستعمل الدواء بعد انتهاء مدة صلاحيته أو عند ملاحظة أي علامة تلف فيه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سقاڤيل 150 ملجم: يحتوي كل قرص مغلف على: إربيسارتان 150 ملجم.<br />سقاڤيل 300 ملجم: يحتوي كل قرص مغلف على: إربيسارتان 300 ملجم.<br />السواغات: لاكتوز، كروسكارميلوز الصوديوم، ميكروكريستالين سيليلوز، ثاني أكسيد<br />السيليكون الغروي، ستيرات المغنيسيوم، هيدروكسي بروبيل ميثيل سيليلوز، بولي ايثيلين<br />جلايكول، ثاني أكسيد التيتانيوم و سيميثيكون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عبوات تحتوي على 30 قرصاً مغلفاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج: شركة تبوك للصناعات الدوائية،<br />طريق المدينة، ص.ب 3633 ، تبوك-المملكة العربية السعودية.<br />لصالح: شركة سقالة فارما، جدة-المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cigavel 300 mg Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cigavel 300 mg: Each film coated tablet contains: Irbesartan 300 mg.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White to off-white colored, oval shaped film coated tablets, engraved with ‘FW’ on one side and plain on
the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Cigavel is indicated in adults for the treatment of essential hypertension.<br />It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes<br />mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Posology<br />The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Cigavel<br />at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.<br />However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and<br />in the elderly over 75 years.<br />In patients insufficiently controlled with 150 mg once daily, the dose of Cigavel can be increased to 300<br />mg, or other antihypertensive agents can be added. In particular, the addition of a diuretic such as<br />hydrochlorothiazide has been shown to have an additive effect with Cigavel (see section 4.5).<br />In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and<br />titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.<br />The demonstration of renal benefit of Cigavel in hypertensive type 2 diabetic patients is based on studies<br />where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood<br />pressure (see section 5.1).<br />Special Populations<br />Renal impairment: no dosage adjustment is necessary in patients with impaired renal function. A lower<br />starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</p><p style="text-align:left">Hepatic impairment: no dosage adjustment is necessary in patients with mild to moderate hepatic<br />impairment. There is no clinical experience in patients with severe hepatic impairment.<br />Older people: although consideration should be given to initiating therapy with 75 mg in patients over 75<br />years of age, dosage adjustment is not usually necessary for older people.<br />Paediatric population: the safety and efficacy of Cigavel in children aged 0 to 18 has not been established.<br />Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can<br />be made.<br />Method of Administration<br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, or to any of the excipients (see section 6.1).
-Second and third trimesters of pregnancy (see sections 4.6).
-Severe hepatic impairment
Do not co-administer Cigavel with aliskiren-containing medicines in patients with diabetes or with
moderate to severe renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections
4.4 and 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in<br />patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction,<br />diarrhoea or vomiting. Such conditions should be corrected before the administration of Cigavel.<br />Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency when<br />patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated<br />with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented<br />with Cigavel, a similar effect should be anticipated with angiotensin-II receptor antagonists.<br />Renal impairment and kidney transplantation: when Cigavel is used in patients with impaired renal<br />function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no<br />experience regarding the administration of Cigavel in patients with a recent kidney transplantation.<br />Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and<br />cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with<br />patients with advanced renal disease. In particular, they appeared less favourable in women and non-white<br />subjects (see section 5.1).<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS):<br />Dual blockade of the RAAS by combining Cigavel with aliskiren is not recommended since there is an<br />increased risk of hypotension, hyperkalaemia, and changes in renal function. The use of Cigavel in<br />combination with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR<br />&lt;60 ml/min/1.73 m&sup2;) (see section 4.5).</p><p style="text-align:left">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system,<br />hyperkalaemia may occur during the treatment with Cigavel, especially in the presence of renal<br />impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum<br />potassium in patients at risk is recommended (see section 4.5).<br />Lithium: the combination of lithium and Cigavel is not recommended (see section 4.5).<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators,<br />special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic<br />cardiomyopathy.<br />Primary aldosteronism: patients with primary aldosteronism generally will not respond to antihypertensive<br />medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Cigavel<br />is not recommended.<br />General: in patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal<br />disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or<br />angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension,<br />azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent,<br />excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular<br />disease could result in a myocardial infarction or stroke.<br />As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists<br />are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly<br />because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).<br />Pregnancy: Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless<br />continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started (see sections 4.3 and 4.6).<br />Lactose: this medicinal product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.<br />Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the<br />current data are insufficient to support an extension of the use in children until further data become<br />available (see sections 4.8, 5.1 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the hypotensive<br />effects of irbesartan; however Cigavel has been safely administered with other antihypertensive agents,<br />such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with<br />high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with<br />Cigavel (see section 4.4).</p><p style="text-align:left">Add Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin<br />receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope,<br />hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.<br />Closely monitor blood pressure, renal function, and electrolytes in patients on [drug] and other agents that<br />affect the RAS.<br />Do not co-administer aliskiren with [drug] in patients with diabetes. Avoid use of aliskiren with [drug] in<br />patients with renal impairment (GFR &amp;amp;amp;lt;60 ml/min).<br />Aliskiren-containing products: the combination of Cigavel with aliskiren-containing medicinal products is<br />contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR &lt;60<br />ml/min/1.73 m&sup2;) and is not recommended in other patients.<br />Potassium supplements and potassium-sparing diuretics: based on experience with the use of other<br />medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing<br />diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that<br />may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is,<br />therefore, not recommended (see section 4.4).<br />Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have<br />been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see<br />section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is<br />recommended.<br />Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously<br />with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day)<br />and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an<br />increased risk of worsening of renal function, including possible acute renal failure, and an increase in<br />serum potassium, especially in patients with poor pre-existing renal function. The combination should be<br />administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy, and<br />periodically thereafter.<br />Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is<br />not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by<br />glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when<br />irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of<br />CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The<br />pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pregnancy:<br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The<br />use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections<br />4.3 and 4.4).<br />Pregnancy Category D,<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during<br />the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be<br />excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor<br />Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is<br />considered essential, patients planning pregnancy should be changed to alternative antihypertensive<br />treatments which have an established safety profile for use in pregnancy.<br />When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity<br />(decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal<br />failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of<br />renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and<br />4.4).<br />Breast-feeding:<br />Because no information is available regarding the use of Cigavel during breast-feeding, Cigavel is not<br />recommended and alternative treatments with better established safety profiles during breast-feeding are<br />preferable, especially while nursing a newborn or preterm infant.<br />It is unknown whether irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites<br />in milk (for details see 5.3).<br />Fertility<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the<br />first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No studies on the effects on the ability to drive and use machines have been performed. Based on its<br />pharmacodynamic properties, irbesartan is unlikely to affect this ability. When driving vehicles or<br />operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not<br />differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical<br />or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated<br />patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range),<br />gender, age, race, or duration of treatment.<br />In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness<br />and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of<br />placebo.<br />The following table presents the adverse drug reactions that were reported in placebo-controlled trials in<br />which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse<br />reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal<br />insufficiency and overt proteinuria and in excess of placebo.<br />The frequency of adverse reactions listed below is defined using the following convention:<br />very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to<br />&lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in<br />order of decreasing seriousness.<br />Adverse reactions additionally reported from post&ndash;marketing experience are also listed. These adverse<br />reactions are derived from spontaneous reports.<br />Immune system disorders:<br />Not known: hypersensitivity reactions such as angioedema, rash, urticaria<br />Metabolism and nutrition disorders:<br />Not known: hyperkalaemia<br />Nervous system disorders:<br />Common: dizziness, orthostatic dizziness*<br />Not known: vertigo, headache<br />Ear and labyrinth disorder:<br />Not known: tinnitus<br />Cardiac disorders:<br />Uncommon: tachycardia</p><p style="text-align:left">Vascular disorders:<br />Common: orthostatic hypotension*<br />Uncommon: flushing<br />Respiratory, thoracic and mediastinal disorders:<br />Uncommon: cough<br />Gastrointestinal disorders:<br />Common: nausea/vomiting<br />Uncommon: diarrhoea, dyspepsia/heartburn<br />Not known: dysgeusia<br />Hepatobiliary disorders:<br />Uncommon: jaundice<br />Not known: hepatitis, abnormal liver function<br />Skin and subcutaneous tissue disorders:<br />Not known: leukocytoclastic vasculitis<br />Musculoskeletal and connective tissue disorders:<br />Common: musculoskeletal pain*<br />Not known: arthralgia, myalgia (in some cases associated with increased plasma creatine<br />kinase levels), muscle cramps<br />Renal and urinary disorders:<br />Not known: impaired renal function including cases of renal failure in patients at risk (see<br />section 4.4)<br />Reproductive system and breast disorders:<br />Uncommon: sexual dysfunction<br />General disorders and administration site conditions:<br />Common: fatigue<br />Uncommon: chest pain<br />Investigations:<br />Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan<br />than with placebo. In diabetic hypertensive patients with microalbuminuria and&nbsp;normal renal function, hyperkalaemia (&ge; 5.5 mEq/L) occurred in 29.4% of the<br />patients in the irbesartan 300 mg group and 22% of the patients in the placebo<br />group. In diabetic hypertensive patients with chronic renal insufficiency and<br />overt proteinuria, hyperkalaemia (&ge; 5.5 mEq/L) occurred in 46.3% of the<br />patients in the irbesartan group and 26.3% of the patients in the placebo group.<br />Common: significant increases in plasma creatine kinase were commonly observed (1.7%)<br />in irbesartan treated subjects. None of these increases were associated with<br />identifiable clinical musculoskeletal events.<br />In 1.7% of hypertensive patients with advanced diabetic renal disease treated<br />with irbesartan, a decrease in haemoglobin*, which was not clinically<br />significant, has been observed.<br />Paediatric population:<br />In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following<br />adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%),<br />dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory<br />abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.<br />To report any side effects<br />National Pharmacovigilance &amp; Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at: +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most<br />likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also<br />occur from overdose. No specific information is available on the treatment of overdose with Cigavel. The<br />patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested<br />measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the<br />treatment of overdose. Irbesartan is not removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.<br />ATC code: C09C A04.<br />Mechanism of action: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1)<br />antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of<br />the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1)<br />receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma<br />aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the<br />recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates<br />angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic<br />activation for its activity.<br />Clinical efficacy:<br />Hypertension<br />Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is doserelated<br />for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg<br />once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-<br />13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.<br />Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure<br />lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70%<br />of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing<br />with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total<br />dose.<br />The blood pressure lowering effect of Cigavel is evident within 1-2 weeks, with the maximal effect<br />occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term<br />therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound<br />hypertension has not been observed.<br />The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not<br />adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to<br />irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6<br />mm Hg (systolic/diastolic).<br />The efficacy of Cigavel is not influenced by age or gender. As is the case with other medicinal products<br />that affect the renin-angiotensin system, black hypertensive patients have notably less response to<br />irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of<br />hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of<br />white patients.</p><p style="text-align:left">There is no clinically important effect on serum uric acid or urinary uric acid secretion.<br />Paediatric population<br />Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated<br />doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension)<br />children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the<br />mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure<br />(SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant<br />difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood<br />pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high<br />dose). Over a subsequent two week period where patients were re-randomized to either active medicinal<br />product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP<br />compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).<br />Hypertension and type 2 diabetes with renal disease<br />The &ldquo;Irbesartan Diabetic Nephropathy Trial (IDNT)&rdquo; shows that irbesartan decreases the progression of<br />renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind,<br />controlled, morbidity and mortality trial comparing Irbesartan, amlodipine and placebo. In 1,715<br />hypertensive patients with type 2 diabetes, proteinuria &ge; 900 mg/day and serum creatinine ranging from<br />1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan on the progression of renal disease and<br />all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg<br />Irbesartan, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. Patients in all treatment groups<br />typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to<br />reach a predefined blood pressure goal of &le; 135/85 mmHg or a 10 mmHg reduction in systolic pressure if<br />baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood<br />pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively.<br />Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum<br />creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the<br />irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo<br />and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk<br />reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint<br />were analysed, no effect in all-cause mortality was observed, while a positive trend in the reduction in<br />ESRD and a significant reduction in doubling of serum creatinine were observed.<br />Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine,<br />and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which<br />represented 32% and 26% of the overall study population respectively, a renal benefit was not evident,<br />although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal<br />cardiovascular events, there was no difference among the three groups in the overall population, although<br />an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was<br />seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of nonfatal<br />MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based<br />regimen, while hospitalization due to heart failure was reduced in the overall population. However, no<br />proper explanation for these findings in women has been identified.</p><p style="text-align:left">The study of the &ldquo;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes<br />Mellitus (IRMA 2)&rdquo; shows that irbesartan 300 mg delays progression to overt proteinuria in patients with<br />microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with<br />type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine &le; 1.5<br />mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Cigavel<br />on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day,<br />and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was &le; 135/85<br />mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists<br />and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal.<br />While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg<br />group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of<br />overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher<br />dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the<br />first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early<br />as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was<br />more frequent in the Cigavel 300 mg group (34%) than in the placebo group (21%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of<br />approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of<br />irbesartan. Plasma protein binding is approximately 96%, with negligible binding to cellular blood<br />components. The volume of distribution is 53 - 93 litres. Following oral or intravenous administration<br />of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.<br />Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating<br />metabolite is irbesartan glucuronide (approximately 6%). In vitro studies indicate that irbesartan is<br />primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A<br />less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal<br />recommended dose) was observed; the mechanism for this is unknown.<br />Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal<br />clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is<br />11 - 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily<br />dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated oncedaily<br />dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female<br />hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No<br />dosage adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat<br />greater in oldersubjects (&ge; 65 years) than those of young subjects (18 - 40 years). However the terminal<br />half-life was not significantly altered. No dosage adjustment is necessary in older people.<br />Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV<br />administration of14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder<br />in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</p><p style="text-align:left">Paediatric population<br />The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of<br />single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four<br />weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve<br />children over 12 years, nine children between 6 and 12 years). Results showed that Cmax, AUC and<br />clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A<br />limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.<br />Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the<br />pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by<br />haemodialysis.<br />Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of<br />irbesartan are not significantly altered.<br />Studies have not been performed in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In nonclinical<br />safety studies, high doses of irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in macaques)<br />caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high<br />doses (&ge; 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular<br />distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by<br />irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the<br />medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced<br />hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10<br />mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan.<br />For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular<br />cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.<br />Fertility and reproductive performance were not affected in studies of male and female rats even at oral<br />doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the<br />highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were observed.<br />Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate<br />that the radiolabeled irbesartan is detected in rat and rabbit fetuses. Irbesartan is excreted in the milk of<br />lactating rats.<br />Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter<br />or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early<br />resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic<br />effects were observed in the rat or rabbit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Lactose Monohydrate fine.<br />Colloidal Silicon Dioxide<br />Microcrystalline Cellulose.<br />Croscarmellose Sodium.<br />Hypromellose 6 cps.<br />Magnesium stearate.<br />Opadry OY 7300.<br />Simethicone Emulsion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Three white PVC /PVDC blisters packed with aluminum foil each blister contains 10 tablets packed<br />in carton with folded leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer by Tabuk Pharmaceutical Manufacturing Co.
Astra industrial group building.
Salah Aldain Road, King abdulaziz Area.
Riyadh, Saudi Arabia
P.O.Box 28170 Riyadh 11437

Marketing by Cigalah Pharma – Jeddah.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>